BuTab (buprenorphine extended release) / Relmada Therapeutics - LARVOL DELTA

Yale investigators' lead grant awarded as part of the NIH HEAL initiative on opioids (Yale School of Medicine) - "Gail D’Onofrio, MD, MS, professor of emergency medicine and public health, and David Fiellin...are lead investigators in a $25.5 Million study being conducted by the National Drug Abuse Treatment Clinical Trials Network’s New England Consortium Nod...The Emergency Department-Initiated buprenorphine Validation Network Trial (ED-INNOVATION) involves 30 diverse emergency departments (EDs) throughout the U.S....The investigators will test an implementation strategy to guide...buprenorphine programs at the sites, and subsequently compare the effectiveness of two formulations of buprenorphine, sublingual versus an extended release 7-day injectable formulation in engaging ED patients with untreated opioid use disorder in medication treatment at 7 days."

Grant • New trial